Therefore, in BRCA-deficient AML, PARP inhibitors may be considered an ideal solution to further prevent removal of DNA lesions and potentially increase the efficacy of DNA-damaging chemotherapeutic drugs, which are commonly used in anticancer therapies. The gene discussed is PARP1; the disease is acute myeloid leukemia.